Eva Feldman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6779933/publications.pdf

Version: 2024-02-01

517 papers	41,334 citations	1980 101 h-index	4203 174 g-index
535 all docs	535 docs citations	535 times ranked	35436 citing authors

#	Article	IF	Citations
1	Diabetic Neuropathies: A statement by the American Diabetes Association. Diabetes Care, 2005, 28, 956-962.	4.3	1,599
2	Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care, 2017, 40, 136-154.	4.3	1,452
3	A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy. Diabetes Care, 1994, 17, 1281-1289.	4.3	1,024
4	Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurology, The, 2012, 11, 521-534.	4.9	866
5	Oxidative Stress in the Pathogenesis of Diabetic Neuropathy. Endocrine Reviews, 2004, 25, 612-628.	8.9	765
6	Diabetic neuropathy. Nature Reviews Disease Primers, 2019, 5, 41.	18.1	692
7	New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron, 2017, 93, 1296-1313.	3.8	599
8	Diabetic neuropathy: Mechanisms to management. , 2008, 120, 1-34.		588
9	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	3.8	517
10	Lifestyle Intervention for Pre-Diabetic Neuropathy. Diabetes Care, 2006, 29, 1294-1299.	4.3	509
11	High glucoseâ€induced oxidative stress and mitochondrial dysfunction in neurons. FASEB Journal, 2002, 16, 1738-1748.	0.2	462
12	The Insulin-Like Growth Factor System and Its Pleiotropic Functions in Brain. Endocrine Reviews, 2005, 26, 916-943.	8.9	431
13	Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nature Reviews Neurology, 2011, 7, 573-583.	4.9	426
14	Neurons Undergo Apoptosis in Animal and Cell Culture Models of Diabetes. Neurobiology of Disease, 1999, 6, 347-363.	2.1	379
15	How does diabetes accelerate Alzheimer disease pathology?. Nature Reviews Neurology, 2010, 6, 551-559.	4.9	362
16	Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes/Metabolism Research and Reviews, 2011, 27, 620-628.	1.7	359
17	Ataxic sensory neuropathy and dorsal root ganglionitis associated with SjÃ¶gren's syndrome. Annals of Neurology, 1990, 27, 304-315.	2.8	350
18	Neurological consequences of obesity. Lancet Neurology, The, 2017, 16, 465-477.	4.9	331

#	Article	IF	Citations
19	Aligned electrospun nanofibers specify the direction of dorsal root ganglia neurite growth. Journal of Biomedical Materials Research - Part A, 2007, 83A, 636-645.	2.1	330
20	Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Typeâ€ƒ1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabetic Medicine, 2012, 29, 937-944.	1.2	325
21	Enhanced glucose control for preventing and treating diabetic neuropathy. The Cochrane Library, 2012, , CD007543.	1.5	323
22	Microvascular Complications of Impaired Glucose Tolerance. Diabetes, 2003, 52, 2867-2873.	0.3	321
23	Effect of Prior Intensive Insulin Treatment During the Diabetes Control and Complications Trial (DCCT) on Peripheral Neuropathy in Type 1 Diabetes During the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care, 2010, 33, 1090-1096.	4.3	315
24	Neuropathy Among the Diabetes Control and Complications Trial Cohort 8 Years After Trial Completion. Diabetes Care, 2006, 29, 340-344.	4.3	313
25	Complications: Neuropathy, Pathogenetic Considerations. Diabetes Care, 1992, 15, 1902-1925.	4.3	279
26	From Fibrosis to Sclerosis. Diabetes, 2008, 57, 1439-1445.	0.3	275
27	Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus. Circulation, 2009, 119, 2886-2893.	1.6	271
28	Control of cell survival by IGF signaling pathways. Growth Hormone and IGF Research, 2002, 12, 193-197.	0.5	262
29	Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy. Diabetes, 2009, 58, 1634-1640.	0.3	258
30	Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. Annals of Neurology, 1990, 27, 316-326.	2.8	255
31	Shortâ€term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB Journal, 2005, 19, 1-24.	0.2	245
32	Lumbar Intraspinal Injection of Neural Stem Cells in Patients with Amyotrophic Lateral Sclerosis: Results of a Phase I Trial in 12 Patients. Stem Cells, 2012, 30, 1144-1151.	1.4	243
33	New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism. Diabetologia, 2019, 62, 1539-1549.	2.9	240
34	Insulin resistance in the nervous system. Trends in Endocrinology and Metabolism, 2012, 23, 133-141.	3.1	235
35	Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Experimental and Molecular Medicine, 2015, 47, e149-e149.	3.2	225
36	Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Reviews in Endocrine and Metabolic Disorders, 2008, 9, 301-314.	2.6	224

#	Article	IF	Citations
37	Dyslipidemia-Induced Neuropathy in Mice. Diabetes, 2009, 58, 2376-2385.	0.3	222
38	Decreased glycolytic and tricarboxylic acid cycle intermediates coincide with peripheral nervous system oxidative stress in a murine model of type 2 diabetes. Journal of Endocrinology, 2013, 216, 1-11.	1.2	222
39	Increased Tau Phosphorylation and Cleavage in Mouse Models of Type 1 and Type 2 Diabetes. Endocrinology, 2009, 150, 5294-5301.	1.4	220
40	Stem cell technology for neurodegenerative diseases. Annals of Neurology, 2011, 70, 353-361.	2.8	219
41	Receptor for Advanced Glycation End Products Activation Injures Primary Sensory Neurons via Oxidative Stress. Endocrinology, 2007, 148, 548-558.	1.4	213
42	Immunosuppressive treatment in multifocal motor neuropathy. Annals of Neurology, 1991, 30, 397-401.	2.8	206
43	Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. European Journal of Pharmacology, 1999, 375, 217-223.	1.7	206
44	Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. Diabetes Care, 2017, 40, 1226-1232.	4.3	202
45	Loss of Myotubularin Function Results in T-Tubule Disorganization in Zebrafish and Human Myotubular Myopathy. PLoS Genetics, 2009, 5, e1000372.	1.5	201
46	Insulin-like Growth Factors Regulate Neuronal Differentiation and Survival. Neurobiology of Disease, 1997, 4, 201-214.	2.1	198
47	The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat.. Journal of Clinical Investigation, 1994, 94, 853-859.	3.9	190
48	Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. JCI Insight, 2016, 1, e86976.	2.3	188
49	Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. Nature Reviews Neurology, 2015, 11, 266-279.	4.9	186
50	Distal Symmetric Polyneuropathy. JAMA - Journal of the American Medical Association, 2015, 314, 2172.	3.8	186
51	The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. Journal of the Peripheral Nervous System, 2008, 13, 218-227.	1.4	184
52	Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: Phase 1 trial outcomes. Annals of Neurology, 2014, 75, 363-373.	2.8	184
53	Loss of Miro1-directed mitochondrial movement results in a novel murine model for neuron disease. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3631-40.	3.3	176
54	Signaling mechanisms that regulate actin-based motility processes in the nervous system. Journal of Neurochemistry, 2002, 83, 490-503.	2.1	175

#	Article	IF	Citations
55	Mouse Models of Diabetic Neuropathy. ILAR Journal, 2014, 54, 259-272.	1.8	173
56	Inflammation as a Therapeutic Target for Diabetic Neuropathies. Current Diabetes Reports, 2016, 16, 29.	1.7	167
57	Insulin-Like Growth Factor-I and Central Nervous System Development. Hormone and Metabolic Research, 1999, 31, 120-125.	0.7	166
58	SUMOylation of the mitochondrial fission protein Drpl occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle. FASEB Journal, 2009, 23, 3917-3927.	0.2	166
59	Intraspinal Stem Cell Transplantation in Amyotrophic Lateral Sclerosis. Neurosurgery, 2012, 71, 405-416.	0.6	160
60	Insulin-like growth factor I rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. , 1996, 166, 323-331.		159
61	Mouse models of diabetic neuropathy. Neurobiology of Disease, 2007, 28, 276-285.	2.1	159
62	Epigenetic Changes in Bone Marrow Progenitor Cells Influence the Inflammatory Phenotype and Alter Wound Healing in Type 2 Diabetes. Diabetes, 2015, 64, 1420-1430.	0.3	159
63	Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. JAMA Neurology, 2017, 74, 1446.	4.5	156
64	IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiology of Disease, 2004, 16, 407-416.	2.1	148
65	The Aetiology of Diabetic Neuropathy: the Combined Roles of Metabolic and Vascular Defects. Diabetic Medicine, 1995, 12, 566-579.	1.2	147
66	Type I Insulin-like Growth Factor Receptor Activation Regulates Apoptotic Proteins. Journal of Biological Chemistry, 1996, 271, 31791-31794.	1.6	147
67	Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark. Diabetes Care, 2018, 41, 1068-1075.	4.3	146
68	Hyperlipidemia: a new therapeutic target for diabetic neuropathy. Journal of the Peripheral Nervous System, 2009, 14, 257-267.	1.4	145
69	The role of growth factors in diabetic peripheral neuropathy. Journal of the Peripheral Nervous System, 2004, 9, 26-53.	1.4	144
70	The design of electrospun PLLA nanofiber scaffolds compatible with serum-free growth of primary motor and sensory neurons. Acta Biomaterialia, 2008, 4, 863-875.	4.1	142
71	Insulin-like Growth Factor-I-mediated Neurite Outgrowth in Vitro Requires Mitogen-activated Protein Kinase Activation. Journal of Biological Chemistry, 1997, 272, 21268-21273.	1.6	141
72	Phosphatidylinositol 3â€kinase and Akt effectors mediate insulinâ€like growth factorâ€I neuroprotection in dorsal root ganglia neurons. FASEB Journal, 2004, 18, 1544-1546.	0.2	141

#	Article	IF	Citations
73	Kindlin-2 Is an Essential Component of Intercalated Discs and Is Required for Vertebrate Cardiac Structure and Function. Circulation Research, 2008, 102, 423-431.	2.0	139
74	Metabolic Syndrome Components Are Associated With Symptomatic Polyneuropathy Independent of Glycemic Status. Diabetes Care, 2016, 39, 801-807.	4.3	139
75	Phenotyping animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study group of the <scp>EASD</scp> (Neurodiab). Journal of the Peripheral Nervous System, 2014, 19, 77-87.	1.4	138
76	Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain, 1995, 118, 359-368.	3.7	137
77	Neuroinflammation, COX-2, and ALSâ€"a dual role?. Experimental Neurology, 2004, 187, 1-10.	2.0	134
78	A Multicenter Study on the Prevalence of Diabetic Neuropathy in Italy. Diabetes Care, 1997, 20, 836-843.	4.3	132
79	Insulin-like growth factor-I prevents caspase-mediated apoptosis in Schwann cells. , 1999, 41, 540-548.		132
80	Oxidative stress and diabetic neuropathy: a new understanding of an old problem. Journal of Clinical Investigation, 2003, 111, 431-433.	3.9	132
81	The identification of gene expression profiles associated with progression of human diabetic neuropathy. Brain, 2011, 134, 3222-3235.	3.7	132
82	Perspective. Academic Medicine, 2012, 87, 266-270.	0.8	132
83	Identification of Epigenetically Altered Genes in Sporadic Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e52672.	1.1	132
84	Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population. JAMA Neurology, 2016, 73, 1468.	4.5	132
85	Tyrosine Phosphorylation of Paxillin and Focal Adhesion Kinase during Insulin-like Growth Factor-I-stimulated Lamellipodial Advance. Journal of Biological Chemistry, 1997, 272, 5214-5218.	1.6	131
86	Diabetes regulates mitochondrial biogenesis and fission in mouse neurons. Diabetologia, 2010, 53, 160-169.	2.9	131
87	Diabetic neuropathy. Current Opinion in Neurology, 2012, 25, 536-541.	1.8	131
88	Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurology, The, 2022, 21, 465-479.	4.9	130
89	Transplantation of spinal cordâ€"derived neural stem cells for ALS. Neurology, 2016, 87, 392-400.	1.5	127
90	An Imbalance Between Excitatory and Inhibitory Neurotransmitters in Amyotrophic Lateral Sclerosis Revealed by Use of 3-T Proton Magnetic Resonance Spectroscopy. JAMA Neurology, 2013, 70, 1009.	4.5	126

#	Article	IF	Citations
91	Mitochondrial biogenesis and fission in axons in cell culture and animal models of diabetic neuropathy. Acta Neuropathologica, 2010, 120, 477-489.	3.9	125
92	Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurology, The, 2022, 21, 480-493.	4.9	124
93	Assessing autonomic dysfunction in early diabetic neuropathy. Neurology, 2011, 76, 1099-1105.	1.5	123
94	Scintigraphic Assessment of Regionalized Defects in Myocardial Sympathetic Innervation and Blood Flow Regulation in Diabetic Patients With Autonomic Neuropathy. Journal of the American College of Cardiology, 1998, 31, 1575-1584.	1.2	120
95	Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Annals of Clinical and Translational Neurology, 2018, 5, 397-405.	1.7	120
96	Oxidative stress and diabetic neuropathy: a new understanding of an old problem. Journal of Clinical Investigation, 2003, 111, 431-433.	3.9	120
97	Insulin-Like Growth Factor-I and Over-Expression of Bcl-xL Prevent Glucose-Mediated Apoptosis in Schwann Cells. Journal of Neuropathology and Experimental Neurology, 2001, 60, 147-160.	0.9	119
98	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	2.8	118
99	Association of Environmental Toxins With Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 803.	4.5	117
100	Insulin-like growth factor-I prevents apoptosis in neurons after nerve growth factor withdrawal. , 1998, 36, 455-467.		115
101	Abnormal RNA stability in amyotrophic lateral sclerosis. Nature Communications, 2018, 9, 2845.	5.8	113
102	Mechanisms of Disease: mitochondria as new therapeutic targets in diabetic neuropathy. Nature Clinical Practice Neurology, 2006, 2, 620-628.	2.7	111
103	Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10190-10195.	3.3	111
104	Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity. EBioMedicine, 2019, 50, 274-289.	2.7	110
105	DCCT and EDIC Studies in Type 1 Diabetes: Lessons for Diabetic Neuropathy Regarding Metabolic Memory and Natural History. Current Diabetes Reports, 2010, 10, 276-282.	1.7	108
106	Transcriptional Profiling of Diabetic Neuropathy in the BKS db/db Mouse. Diabetes, 2011, 60, 1981-1989.	0.3	107
107	Decreased motor cortex Î³-aminobutyric acid in amyotrophic lateral sclerosis. Neurology, 2012, 78, 1596-1600.	1.5	107
108	Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes, 2020, 69, 1000-1010.	0.3	106

#	Article	IF	Citations
109	Bidirectional Regulation of p38 Kinase and c-Jun N-terminal Protein Kinase by Insulin-like Growth Factor-I. Journal of Biological Chemistry, 1998, 273, 14560-14565.	1.6	105
110	Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim, Bax and the fission protein Drp1. Neurobiology of Disease, 2006, 23, 11-22.	2.1	105
111	Characterization of Insulinâ€Like Growth Factorâ€I and Its Receptor and Binding Proteins in Transected Nerves and Cultured Schwann Cells. Journal of Neurochemistry, 1996, 66, 525-536.	2.1	102
112	Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Research, 1996, 56, 4522-9.	0.4	102
113	Zebrafish models of collagen VI-related myopathies. Human Molecular Genetics, 2010, 19, 2433-2444.	1.4	100
114	Update on diabetic neuropathy. Current Opinion in Neurology, 2002, 15, 595-603.	1.8	99
115	Insulin-Like Growth Factor-I Prevents Apoptosis in Sympathetic Neurons Exposed to High Glucose. Hormone and Metabolic Research, 1999, 31, 90-96.	0.7	97
116	Diabetic neuropathy: scope of the syndrome. American Journal of Medicine, 1999, 107, 2-8.	0.6	96
117	Sensory Neurons and Schwann Cells Respond to Oxidative Stress by Increasing Antioxidant Defense Mechanisms. Antioxidants and Redox Signaling, 2009, 11, 425-438.	2.5	96
118	Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. Journal of the Neurological Sciences, 2001, 189, 3-5.	0.3	95
119	SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Experimental Neurology, 2007, 208, 216-227.	2.0	95
120	Human Neural Stem Cell Replacement Therapy for Amyotrophic Lateral Sclerosis by Spinal Transplantation. PLoS ONE, 2012, 7, e42614.	1.1	95
121	25 years of neuroimaging in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2013, 9, 513-524.	4.9	93
122	Intraspinal Stem Cell Transplantation in Amyotrophic Lateral Sclerosis. Neurosurgery, 2014, 74, 77-87.	0.6	93
123	Evidenceâ€based Guideline: Treatment of Painful Diabetic Neuropathy. PM and R, 2011, 3, 345.	0.9	91
124	Role of Neurologists and Diagnostic Tests on the Management of Distal Symmetric Polyneuropathy. JAMA Neurology, 2014, 71, 1143.	4.5	91
125	COVID-19 and Diabetes: A Collision and Collusion of Two Diseases. Diabetes, 2020, 69, 2549-2565.	0.3	91
126	Increased Axonal Regeneration and Swellings in Intraepidermal Nerve Fibers Characterize Painful Phenotypes of Diabetic Neuropathy. Journal of Pain, 2013, 14, 941-947.	0.7	90

#	Article	IF	Citations
127	Hyperinsulinemia Induces Insulin Resistance in Dorsal Root Ganglion Neurons. Endocrinology, 2011, 152, 3638-3647.	1.4	88
128	The metabolic syndrome and neuropathy: Therapeutic challenges and opportunities. Annals of Neurology, 2013, 74, 397-403.	2.8	88
129	New insights into the pathogenesis of diabetic neuropathy. Current Opinion in Neurology, 1999, 12, 553-563.	1.8	88
130	Diabetic neuropathy: what does the future hold?. Diabetologia, 2020, 63, 891-897.	2.9	84
131	Peripheral Neuropathy in Adolescents and Young Adults With Type 1 and Type 2 Diabetes From the SEARCH for Diabetes in Youth Follow-up Cohort. Diabetes Care, 2013, 36, 3903-3908.	4.3	83
132	Nerve Growth Factor Mediates Mechanical Allodynia in a Mouse Model of Type 2 Diabetes. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1229-1243.	0.9	81
133	Human neural stem cell transplantation improves cognition in a murine model of Alzheimerâ€™s disease. Scientific Reports, 2018, 8, 14776.	1.6	81
134	Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain, 2021, 144, 1632-1645.	3.7	81
135	Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. Neurobiology of Disease, 2008, 30, 420-429.	2.1	80
136	The Association of Exposure to Lead, Mercury, and Selenium and the Development of Amyotrophic Lateral Sclerosis and the Epigenetic Implications. Neurodegenerative Diseases, 2011, 8, 1-8.	0.8	80
137	Cortical Neurons Develop Insulin Resistance and Blunted Akt Signaling: A Potential Mechanism Contributing to Enhanced Ischemic Injury in Diabetes. Antioxidants and Redox Signaling, 2011, 14, 1829-1839.	2.5	80
138	PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models. Journal of Clinical Investigation, 2016, 126, 3613-3625.	3.9	80
139	Clinical Testing in Diabetic Peripheral Neuropathy. Canadian Journal of Neurological Sciences, 1994, 21, S3-S7.	0.3	79
140	Kindlin-2 is required for myocyte elongation and is essential for myogenesis. BMC Cell Biology, 2008, 9, 36.	3.0	79
141	SciMiner: web-based literature mining tool for target identification and functional enrichment analysis. Bioinformatics, 2009, 25, 838-840.	1.8	78
142	mnd2: A New Mouse Model of Inherited Motor Neuron Disease. Genomics, 1993, 16, 669-677.	1.3	77
143	New Insights into the Mechanisms of Diabetic Neuropathy. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 227-236.	2.6	77
144	The Importance of Rare Subtypes in Diagnosis and Treatment of Peripheral Neuropathy. JAMA Neurology, 2015, 72, 1510.	4.5	77

#	Article	IF	Citations
145	Vascular endothelial growth factor prevents G93Aâ€SOD1â€induced motor neuron degeneration. Developmental Neurobiology, 2009, 69, 871-884.	1.5	76
146	Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. Molecular and Cellular Neurosciences, 2016, 71, 34-45.	1.0	76
147	Abnormal Muscle Spindle Innervation and Large-Fiber Neuropathy in Diabetic Mice. Diabetes, 2008, 57, 1693-1701.	0.3	75
148	Accelerated neuritogenesis and maturation of primary spinal motor neurons in response to nanofibers. Developmental Neurobiology, 2010, 70, 589-603.	1.5	75
149	Translational stem cell therapy for amyotrophic lateral sclerosis. Nature Reviews Neurology, 2012, 8, 172-176.	4.9	74
150	Increased lipogenesis and impaired Î²-oxidation predict type 2 diabetic kidney disease progression in American Indians. JCI Insight, 2019, 4, .	2.3	74
151	Insulin-like growth factor-I signaling in human neuroblastoma cells. Oncogene, 2004, 23, 130-141.	2.6	73
152	Zebrafish MTMR14 is required for excitationâ€“contraction coupling, developmental motor function and the regulation of autophagy. Human Molecular Genetics, 2010, 19, 2668-2681.	1.4	73
153	Altered Excitation-inhibition Balance in the Brain of Patients with Diabetic Neuropathy. Academic Radiology, 2012, 19, 607-612.	1.3	73
154	ER Stress in Diabetic Peripheral Neuropathy: A New Therapeutic Target. Antioxidants and Redox Signaling, 2014, 21, 621-633.	2.5	73
155	Matrin 3-dependent neurotoxicity is modified by nucleic acid binding and nucleocytoplasmic localization. ELife, 2018, 7, .	2.8	73
156	Studies on the localization of newly added membrane in growing neurites. Journal of Neurobiology, 1981, 12, 591-598.	3.7	72
157	Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2008, 295, F1071-F1081.	1.3	72
158	Insulin-Like Growth Factor-I Receptor Expression Regulates Neuroblastoma Metastasis to Bone. Cancer Research, 2006, 66, 6570-6578.	0.4	71
159	Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiology of Disease, 2009, 33, 473-481.	2.1	71
160	Mediators of diabetic neuropathy: is hyperglycemia the only culprit?. Current Opinion in Endocrinology, Diabetes and Obesity, 2017, 24, 103-111.	1.2	71
161	Skeletal muscle weakness due to deficiency of CuZn-superoxide dismutase is associated with loss of functional innervation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 301, R1400-R1407.	0.9	70
162	Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy. Journal of Molecular Medicine, 2013, 91, 727-737.	1.7	70

#	Article	IF	Citations
163	Diagnostic Accuracy of Diffusion Tensor Imaging in Amyotrophic Lateral Sclerosis. Academic Radiology, 2013, 20, 1099-1106.	1.3	70
164	Vibration Perception Threshold as a Measure of Distal Symmetrical Peripheral Neuropathy in Type 1 Diabetes. Diabetes Care, 2010, 33, 2635-2641.	4.3	69
165	Hydrogen peroxide-induced Akt phosphorylation regulates Bax activation. Biochimie, 2009, 91, 577-585.	1.3	68
166	Concise Review: Stem Cell Therapies for Amyotrophic Lateral Sclerosis: Recent Advances and Prospects for the Future. Stem Cells, 2014, 32, 1099-1109.	1.4	68
167	BTBR ob/ob mice as a novel diabetic neuropathy model: Neurological characterization and gene expression analyses. Neurobiology of Disease, 2015, 73, 348-355.	2.1	68
168	Dyslipidemia impairs mitochondrial trafficking and function in sensory neurons. FASEB Journal, 2018, 32, 195-207.	0.2	68
169	Chronic inflammatory demyelinating polyradiculoneuropathy. Neurology, 1992, 42, 1157-1157.	1.5	67
170	Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. Journal of the Neurological Sciences, 1993, 120, 60-63.	0.3	67
171	Acetyl-l-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K-ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat. Metabolism: Clinical and Experimental, 1996, 45, 865-872.	1.5	67
172	GTPases and Phosphatidylinositol 3-Kinase Are Critical for Insulin-like Growth Factor-I-mediated Schwann Cell Motility. Journal of Biological Chemistry, 2000, 275, 27197-27204.	1.6	67
173	GTPases and phosphatidylinositol 3-kinase are critical for insulin-like growth factor-I-mediated Schwann cell motility. Journal of Biological Chemistry, 2000, 275, 27197-204.	1.6	67
174	Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. Journal of the Neurological Sciences, 1997, 150, 59-62.	0.3	66
175	Insulin Receptor Substrate 2 And Shc Play Different Roles In Insulin-like Growth Factor I Signaling. Journal of Biological Chemistry, 1998, 273, 34543-34550.	1.6	66
176	Criteria for Creating and Assessing Mouse Models of Diabetic Neuropathy. Current Drug Targets, 2008, 9, 3-13.	1.0	66
177	Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Cohort Study. Pediatric Diabetes, 2018, 19, 680-689.	1.2	66
178	Environmental Risk Factors and Amyotrophic Lateral Sclerosis (ALS): A Case-Control Study of ALS in Michigan. PLoS ONE, 2014, 9, e101186.	1.1	66
179	Aldose reductase inhibitors: An approach to the treatment of diabetic nerve damage. Diabetes/metabolism Reviews, 1993, 9, 189-217.	0.2	65
180	Evidenceâ€based guideline: Treatment of painful diabetic neuropathyâ€"report of the american association of neuromuscular and electrodiagnostic medicine, the american academy of neurology, and the american academy of physical medicine & rehabilitation. Muscle and Nerve, 2011, 43, 910-917.	1.0	65

#	Article	IF	Citations
181	Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e242.	3.1	65
182	Insulin-Like Growth Factors in the Peripheral Nervous System. Endocrinology, 2008, 149, 5963-5971.	1.4	64
183	Stem cell technology for the study and treatment of motor neuron diseases. Regenerative Medicine, 2011, 6, 201-213.	0.8	64
184	Biology of diabetic neuropathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 115, 591-606.	1.0	64
185	Hyperglycemia-Induced Tau Cleavage in vitro and in vivo: A Possible Link Between Diabetes and Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 727-739.	1.2	64
186	Insulin-like growth factor-I is an osmoprotectant in human neuroblastoma cells. Neuroscience, 1997, 79, 525-534.	1.1	63
187	Impaired glucose tolerance?does it cause neuropathy?. Muscle and Nerve, 2001, 24, 1109-1112.	1.0	63
188	The dual roles of immunity in ALS: Injury overrides protection. Neurobiology of Disease, 2015, 77, 1-12.	2.1	63
189	Human Cortical Neural Stem Cells Expressing Insulin-Like Growth Factor-I: A Novel Cellular Therapy for Alzheimer's Disease. Stem Cells Translational Medicine, 2016, 5, 379-391.	1.6	63
190	Insulin-like Growth Factor-I in Muscle Metabolism and Myotherapies. Neurobiology of Disease, 2001, 8, 541-554.	2.1	62
191	Predictors of noninvasive ventilation tolerance in patients with amyotrophic lateral sclerosis. Muscle and Nerve, 2005, 32, 808-811.	1.0	62
192	Reliability of quantitative sudomotor axon reflex testing and quantitative sensory testing in neuropathy of impaired glucose regulation. Muscle and Nerve, 2009, 39, 529-535.	1.0	61
193	Insulin-like growth factor I stimulates motility in human neuroblastoma cells. Oncogene, 2001, 20, 7542-7550.	2.6	60
194	Triglycerides and Amputation Risk in Patients With Diabetes. Diabetes Care, 2011, 34, 635-640.	4.3	60
195	Caveolin-1 expression in Schwann cells. , 1999, 27, 39-52.		59
196	Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. Journal of Cellular Physiology, 2000, 182, 24-32.	2.0	59
197	New developments in diabetic neuropathy. Current Opinion in Neurology, 2005, 18, 586-590.	1.8	59
198	Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 63-73.	2.3	59

#	Article	IF	Citations
199	IGF-I receptor activation and BCL-2 overexpression prevent early apoptotic events in human neuroblastoma. Cell Death and Differentiation, 2000, 7, 654-665.	5.0	58
200	The Antioxidant Response as a Drug Target in Diabetic Neuropathy. Current Drug Targets, 2008, 9, 94-100.	1.0	58
201	Disorders of Cranial Nerves IX and X. Seminars in Neurology, 2009, 29, 085-092.	0.5	58
202	p38 Mediates Mechanical Allodynia in a Mouse Model of Type 2 Diabetes. Molecular Pain, 2010, 6, 1744-8069-6-28.	1.0	58
203	Gene expression of the insulin-like growth factors and their receptors in cultured human retinal pigment epithelial cells. Molecular Brain Research, 1992, 12, 181-186.	2.5	57
204	Insulin-like Growth Factor-II as a Paracrine Growth Factor in Human Neuroblastoma Cells. Experimental Cell Research, 1995, 221, 179-186.	1.2	57
205	IGF-I promotes Schwann cell motility and survival via activation of Akt. Molecular and Cellular Endocrinology, 2000, 170, 211-215.	1.6	57
206	Polyneuropathy with impaired glucose tolerance: Implications for diagnosis and therapy. Current Treatment Options in Neurology, 2005, 7, 33-42.	0.7	57
207	Peripheral nervous system insulin resistance in ob/ob mice. Acta Neuropathologica Communications, 2013, 1, 15.	2.4	57
208	Insulin-like Growth Factors as Regulators of Cell Motility Signaling Mechanisms. Trends in Endocrinology and Metabolism, 1997, 8, 1-6.	3.1	56
209	The effects of anesthesia on measures of nerve conduction velocity in male C57Bl6/J mice. Neuroscience Letters, 2010, 483, 127-131.	1.0	56
210	Cervical Multilevel Intraspinal Stem Cell Therapy. Spine, 2011, 36, E164-E171.	1.0	56
211	Neuromuscular effects of G93A-SOD1 expression in zebrafish. Molecular Neurodegeneration, 2012, 7, 44.	4.4	56
212	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	3.8	56
213	Substrate patterning: an emerging technology for the study of neuronal behavior. Experimental Neurology, 2003, 184, 89-96.	2.0	55
214	Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors, 2009, 27, 133-140.	0.5	55
215	Rosiglitazone Treatment Reduces Diabetic Neuropathy in Streptozotocin-Treated DBA/2J Mice. Endocrinology, 2008, 149, 4928-4937.	1.4	53
216	Dietary reversal of neuropathy in a murine model of prediabetes and the metabolic syndrome. DMM Disease Models and Mechanisms, 2017, 10, 717-725.	1.2	53

#	Article	IF	Citations
217	The Divergent Roles of Dietary Saturated and Monounsaturated Fatty Acids on Nerve Function in Murine Models of Obesity. Journal of Neuroscience, 2019, 39, 3770-3781.	1.7	52
218	IGF-I Promotes Peripheral Nervous System Myelination. Annals of the New York Academy of Sciences, 1999, 883, 124-130.	1.8	51
219	Mitochondrial DNA (mtDNA) Biogenesis: Visualization and Duel Incorporation of BrdU and EdU Into Newly Synthesized mtDNA In Vitro. Journal of Histochemistry and Cytochemistry, 2010, 58, 207-218.	1.3	51
220	Untargeted metabolomics yields insight into ALS disease mechanisms. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1329-1338.	0.9	51
221	Differential Regulation of Focal Adhesion Kinase and Mitogenâ€Activated Protein Kinase Tyrosine Phosphorylation During Insulinâ€Like Growth Factorâ€Iâ€Mediated Cytoskeletal Reorganization. Journal of Neurochemistry, 1998, 71, 1333-1336.	2.1	50
222	Adeno-associated viral vector gene expression in the adult rat spinal cord following remote vector delivery. Neurobiology of Disease, 2003, 14, 535-541.	2.1	50
223	Intraneural Colchicine Inhibition of Adenoviral and Adeno-associated Viral Vector Remote Spinal Cord Gene Delivery. Neurosurgery, 2003, 52, 381-387.	0.6	50
224	Cell Culture Modeling to Test Therapies Against Hyperglycemia-Mediated Oxidative Stress and Injury. Antioxidants and Redox Signaling, 2005, 7, 1494-1506.	2.5	50
225	The Management of Diabetic Neuropathy in CKD. American Journal of Kidney Diseases, 2010, 55, 365-385.	2.1	50
226	Temporal evolution of the microbiome, immune system, and epigenome with disease progression in ALS mice. DMM Disease Models and Mechanisms, 2019, 13, .	1.2	50
227	Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance. Muscle and Nerve, 1993, 16, 77-83.	1.0	49
228	Immunohistochemical localization of insulin-like growth factor-II (IGF-II) and IGF-binding protein-2 during development in the rat brain.. Endocrinology, 1994, 135, 540-547.	1.4	49
229	The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes. Diabetes, 2015, 64, 3294-3304.	0.3	49
230	Idiopathic distal sensory polyneuropathy. Neurology, 2020, 95, 1005-1014.	1.5	49
231	Tyrosine Phosphorylation and Enhanced Expression of Paxillin during Neuronal Differentiation in Vitro. Journal of Biological Chemistry, 1996, 271, 5957-5960.	1.6	48
232	N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells. Oncogene, 2002, 21, 4549-4557.	2.6	48
233	Integrin Expression Regulates Neuroblastoma Attachment and Migration. Neoplasia, 2004, 6, 332-342.	2.3	48
234	Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. Journal of Diabetes and Its Complications, 2015, 29, 1287-1294.	1.2	48

#	Article	IF	Citations
235	Central Obesity is Associated With Neuropathy in the Severely Obese. Mayo Clinic Proceedings, 2020, 95, 1342-1353.	1.4	48
236	Insulin-like growth factor I regulates c-myc and GAP-43 messenger ribonucleic acid expression in SH-SY5Y human neuroblastoma cells.. Endocrinology, 1993, 132, 2017-2023.	1.4	46
237	Insulin-like growth factor-I regulates glucose-induced mitochondrial depolarization and apoptosis in human neuroblastoma. Cell Death and Differentiation, 2004, 11, 885-896.	5.0	46
238	Analysis of graft survival in a trial of stem cell transplant in ALS. Annals of Clinical and Translational Neurology, 2014, 1, 900-908.	1.7	46
239	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	4.5	46
240	Dysphagia in elderly men with myasthenia gravis. Journal of the Neurological Sciences, 1996, 138, 49-52.	0.3	45
241	Multimodal <scp>MRI</scp> as a diagnostic biomarker for amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2014, 1, 107-114.	1.7	45
242	Insulin Resistance Prevents AMPK-induced Tau Dephosphorylation through Akt-mediated Increase in AMPKSer-485 Phosphorylation. Journal of Biological Chemistry, 2015, 290, 19146-19157.	1.6	45
243	Notch Signaling Regulates Motor Neuron Differentiation of Human Embryonic Stem Cells. Stem Cells, 2015, 33, 403-415.	1.4	45
244	Comparative RNAâ€Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease. Journal of Cellular and Molecular Medicine, 2017, 21, 2140-2152.	1.6	45
245	Schwann cell caveolin-1 expression increases during myelination and decreases after axotomy. Glia, 2002, 38, 191-199.	2.5	44
246	Nerve growth factor/p38 signaling increases intraepidermal nerve fiber densities in painful neuropathy of type 2 diabetes. Neurobiology of Disease, 2012, 45, 280-287.	2.1	44
247	Long-Chain Acyl Coenzyme A Synthetase 1 Overexpression in Primary Cultured Schwann Cells Prevents Long Chain Fatty Acid-Induced Oxidative Stress and Mitochondrial Dysfunction. Antioxidants and Redox Signaling, 2014, 21, 588-600.	2.5	44
248	Longâ€term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Annals of Clinical and Translational Neurology, 2018, 5, 730-740.	1.7	44
249	Surgical Decompression for Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2007, 30, 421-422.	4.3	43
250	Central nervous system endoplasmic reticulum stress in a murine model of type 2 diabetes. Diabetologia, 2012, 55, 2276-2284.	2.9	43
251	Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia, 2013, 56, 1835-1844.	2.9	43
252	Metabolic Factors, Lifestyle Habits, and Possible Polyneuropathy in Early Type 2 Diabetes: A Nationwide Study of 5,249 Patients in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Cohort. Diabetes Care, 2020, 43, 1266-1275.	4.3	43

#	Article	IF	Citations
253	Regulation of insulin-like growth factor-II expression and its role in autocrine growth of human neuroblastoma cells. Journal of Cellular Physiology, 1993, 155, 290-300.	2.0	42
254	N-Myc overexpression leads to decreased Î²1 integrin expression and increased apoptosis in human neuroblastoma cells. Oncogene, 2003, 22, 2664-2673.	2.6	42
255	The myopathy-causing mutation DNM2-S619L leads to defective tubulation in vitro and in developing zebrafish. DMM Disease Models and Mechanisms, 2014, 7, 157-61.	1.2	42
256	Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: An inflammatory story. Experimental Neurology, 2018, 305, 33-43.	2.0	42
257	Integrated lipidomic and transcriptomic analyses identify altered nerve triglycerides in mouse models of prediabetes and type 2 diabetes. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	42
258	Insulin-like growth factor-I (IGF-I) and IGF binding protein-5 in Schwann cell differentiation. Journal of Cellular Physiology, 1997, 171, 161-167.	2.0	41
259	Membrane Traffic and Muscle: Lessons from Human Disease. Traffic, 2008, 9, 1035-1043.	1.3	41
260	Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression. Gene Therapy, 2009, 16, 1292-1299.	2.3	41
261	Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials. Expert Opinion on Investigational Drugs, 2019, 28, 525-543.	1.9	41
262	Chain length of saturated fatty acids regulates mitochondrial trafficking and function in sensory neurons. Journal of Lipid Research, 2019, 60, 58-70.	2.0	41
263	Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy. Journal of the Peripheral Nervous System, 2020, 25, 76-84.	1.4	41
264	Characterization of Adenoviral Gene Expression in Spinal Cord after Remote Vector Delivery. Neurosurgery, 1999, 45, 131-138.	0.6	40
265	Insulin-like Growth Factor I Prevents Mannitol-induced Degradation of Focal Adhesion Kinase and Akt. Journal of Biological Chemistry, 2002, 277, 27393-27400.	1.6	40
266	Dietary Reversal Ameliorates Short- and Long-Term Memory Deficits Induced by High-fat Diet Early in Life. PLoS ONE, 2016, 11, e0163883.	1.1	40
267	Gender-specific differences in diabetic neuropathy in BTBR ob/ob mice. Journal of Diabetes and Its Complications, 2016, 30, 30-37.	1.2	40
268	Conserved Transcriptional Signatures in Human and Murine Diabetic Peripheral Neuropathy. Scientific Reports, 2018, 8, 17678.	1.6	40
269	Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19. Diabetes Care, 2022, 45, 692-700.	4.3	40
270	Insulin-Like Growth Factors in the Treatment of Neurological Disease. , 2005, 9, 135-159.		39

#	Article	IF	Citations
271	Bioenergetics in diabetic neuropathy: what we need to know. Journal of the Peripheral Nervous System, 2012, 17, 10-14.	1.4	39
272	The Role of Oxidative Stress in Nervous System Aging. PLoS ONE, 2013, 8, e68011.	1.1	39
273	High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 907-912.	0.9	39
274	The emerging role of dyslipidemia in diabetic microvascular complications. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 115-123.	1.2	39
275	Regulation of Insulin-Like Growth Factor-Binding Protein-5 Expression during Schwann Cell Differentiation1. Endocrinology, 1999, 140, 4478-4485.	1.4	38
276	Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. Diabetes Care, 2016, 39, 1587-1593.	4.3	38
277	Shared and distinct lipid-lipid interactions in plasma and affected tissues in a diabetic mouse model. Journal of Lipid Research, 2018, 59, 173-183.	2.0	38
278	The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease. Neurobiology of Disease, 2019, 132, 104541.	2.1	38
279	Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease?. Experimental Neurology, 2019, 320, 112967.	2.0	38
280	The Prevalence and Determinants of Cognitive Deficits and Traditional Diabetic Complications in the Severely Obese. Diabetes Care, 2020, 43, 683-690.	4.3	38
281	Longitudinal patient-oriented outcomes in neuropathy. Neurology, 2015, 85, 71-79.	1.5	37
282	Gene expression of the insulin-like growth factors and their receptors in human neuroblastoma cell lines. Molecular Brain Research, 1992, 15, 241-246.	2.5	36
283	Intraspinal stem cell transplantation for amyotrophic lateral sclerosis. Annals of Neurology, 2016, 79, 342-353.	2.8	36
284	Tests and Expenditures in the Initial Evaluation of Peripheral Neuropathy. Archives of Internal Medicine, 2012, 172, 127.	4.3	35
285	Differential Regulation of Insulin Receptor Substrate-2 and Mitogen-Activated Protein Kinase Tyrosine Phosphorylation by Phosphatidylinositol 3-Kinase Inhibitors in SH-SY5Y Human Neuroblastoma Cells**This work was supported by NIH Grants R29-NS-32843 and R01-NS-36778, grants from the American Diabetes Association and Juvenile Diabetes Foundation (to E.L.F.), and a grant from the Millie Schembechler Adrenal Research Fund of the University of Michigan Comprehensive Cancer Center (to) Tj ETQq1 1 0.784314 rgBT /Ov	1.4	34
286	Ontology-based Brucella vaccine literature indexing and systematic analysis of gene-vaccine association network. BMC Immunology, 2011, 12, 49.	0.9	34
287	Transcriptional networks of murine diabetic peripheral neuropathy and nephropathy: common and distinct gene expression patterns. Diabetologia, 2016, 59, 1297-1306.	2.9	34
288	Reduced intraepidermal nerve fiber density after a sustained increase in insular glutamate: a proof-of-concept study examining the pathogenesis of small fiber pathology in fibromyalgia. Pain Reports, 2017, 2, e590.	1.4	34

#	Article	IF	Citations
289	Effects of serum and insulin-like growth factors on human neuroblastoma cell growth. Regulatory Peptides, 1993, 48, 217-224.	1.9	33
290	Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2005, 10, 831-840.	2.2	33
291	Receptor-Coupled Phosphoinositide Hydrolysis in Human Retinal Pigment Epithelium. Journal of Neurochemistry, 1991, 56, 2094-2100.	2.1	32
292	Immunohistochemical localization of insulin-like growth factor binding protein-5 in the developing rat nervous system. Developmental Brain Research, 1996, 92, 211-218.	2.1	32
293	Longitudinal assessment of noninvasive positive pressure ventilation adjustments in ALS patients. Journal of the Neurological Sciences, 2006, 247, 59-63.	0.3	32
294	Insulin-like growth factor-I and Bcl-XL inhibit c-jun N-terminal kinase activation and rescue Schwann cells from apoptosis. Journal of Neurochemistry, 2008, 76, 935-943.	2.1	32
295	Altered plasma serine and 1-deoxydihydroceramide profiles are associated with diabetic neuropathy in type 2 diabetes and obesity. Journal of Diabetes and Its Complications, 2021, 35, 107852.	1.2	32
296	Interferon-Î³ inhibits DNA synthesis and insulin-like growth factor-II expression in human neuroblastoma cells. Journal of Neuroscience Research, 1993, 34, 489-501.	1.3	31
297	IGF receptor function and regulation in autocrine human neuroblastoma cell growth. Regulatory Peptides, 1993, 48, 225-232.	1.9	31
298	Identification of Factors Associated With Sural Nerve Regeneration and Degeneration in Diabetic Neuropathy. Diabetes Care, 2013, 36, 4043-4049.	4.3	31
299	Integrated Systems Pharmacology Analysis of Clinical Drugâ€‐Induced Peripheral Neuropathy. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-11.	1.3	31
300	Disorders of mitochondrial dynamics in peripheral neuropathy: Clues from hereditary neuropathy and diabetes. International Review of Neurobiology, 2019, 145, 127-176.	0.9	31
301	Optimization of Immunosuppressive Therapy for Spinal Grafting of Human Spinal Stem Cells in a Rat Model of ALS. Cell Transplantation, 2011, 20, 1153-1161.	1.2	30
302	Emerging understanding of the genotypeâ€“phenotype relationship in amyotrophic lateral sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 603-623.	1.0	30
303	Pathogenesis of Diabetic Neuropathy. , 1998, , 13-48.		30
304	Insulin-like growth factor II in the pathogenesis of human neuroblastoma. American Journal of Pathology, 1995, 147, 1790-8.	1.9	30
305	Diabetic neuropathies. Practical Neurology, 2007, 7, 82-92.	0.5	30
306	Histological localization of binding sites of Î±-bungarotoxin and of antibodies specific to acetylcholine receptor in goldfish optic nerve and tectum. Brain Research, 1980, 194, 171-180.	1.1	29

#	Article	IF	Citations
307	Degradation and Dephosphorylation of Focal Adhesion Kinase During Okadaic Acid-Induced Apoptosis in Human Neuroblastoma Cells. Neoplasia, 2003, 5, 405-416.	2.3	29
308	Literature-based discovery of diabetes- and ROS-related targets. BMC Medical Genomics, 2010, 3, 49.	0.7	29
309	Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy. Experimental Neurology, 2013, 239, 102-110.	2.0	29
310	Early life metal dysregulation in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 872-882.	1.7	29
311	Granulomatous myositis, primary biliary cirrhosis, pancytopenia, and thymoma. Muscle and Nerve, 2000, 23, 1133-1136.	1.0	28
312	Juvenile murine models of prediabetes and type 2 diabetes develop neuropathy. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	28
313	Pathway crosstalk perturbation network modeling for identification of connectivity changes induced by diabetic neuropathy and pioglitazone. BMC Systems Biology, 2019, 13, 1.	3.0	28
314	Genome-wide DNA methylation profiling of human diabetic peripheral neuropathy in subjects with type 2 diabetes mellitus. Epigenetics, 2019, 14, 766-779.	1.3	28
315	Pathogenesis of diabetic neuropathy. Clinical Neuroscience, 1997, 4, 365-70.	0.1	28
316	Glial-neuron crosstalk in health and disease: A focus on metabolism, obesity, and cognitive impairment. Neurobiology of Disease, 2022, 170, 105766.	2.1	28
317	Differences between collagen morphologies, properties and distribution in diabetic and normal biobreeding and Sprague–Dawley rat sciatic nerves. Journal of Biomechanics, 2004, 37, 879-888.	0.9	27
318	Cofilin activity during insulin-like growth factor I-stimulated neuroblastoma cell motility. Cellular and Molecular Life Sciences, 2005, 62, 461-470.	2.4	27
319	Global Metabolomic and Isobaric Tagging Capillary Liquid Chromatography–Tandem Mass Spectrometry Approaches for Uncovering Pathway Dysfunction in Diabetic Mouse Aorta. Journal of Proteome Research, 2014, 13, 6121-6134.	1.8	27
320	Autocrine Production of IGF-I Increases Stem Cell-Mediated Neuroprotection. Stem Cells, 2015, 33, 1480-1489.	1.4	27
321	Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-specific Manner. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	27
322	Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes. Annals of Clinical and Translational Neurology, 2021, 8, 1292-1307.	1.7	27
323	Neurodegeneration and early lethality in superoxide dismutase 2-deficient mice: A comprehensive analysis of the central and peripheral nervous systems. Neuroscience, 2012, 212, 201-213.	1.1	26
324	The role of endoplasmic reticulum stress in hippocampal insulin resistance. Experimental Neurology, 2016, 277, 261-267.	2.0	26

#	Article	IF	Citations
325	Better diagnostic accuracy of neuropathy in obesity: A new challenge for neurologists. Clinical Neurophysiology, 2018, 129, 654-662.	0.7	26
326	Genome-wide profiling of DNA methylation and gene expression identifies candidate genes for human diabetic neuropathy. Clinical Epigenetics, 2020, 12, 123.	1.8	26
327	IGFs and the Nervous System. , 1999, , 425-455.		26
328	Delivery of an Adenoviral Vector to the Crushed Recurrent Laryngeal Nerve. Laryngoscope, 2003, 113, 985-989.	1.1	25
329	Insulin receptor substrate (IRS)-2, not IRS-1, protects human neuroblastoma cells against apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 665-673.	2.2	25
330	The role of MTMR14 in autophagy and in muscle disease. Autophagy, 2010, 6, 819-820.	4.3	25
331	A leptin-regulated circuit controls glucose mobilization during noxious stimuli. Journal of Clinical Investigation, 2017, 127, 3103-3113.	3.9	25
332	Acute pandysautonomic neuropathy. Neurology, 1991, 41, 746-748.	1.5	25
333	Caveolin-1 expression in Schwann cells. Glia, 1999, 27, 39-52.	2.5	25
334	Mannose 6-phosphate potentiates insulin-like growth factor II effects in cultured human neuroblastoma cells. Brain Research, 1991, 562, 111-116.	1.1	24
335	Remote Delivery of rAAV-GFP to the Rat Brainstem Through the Recurrent Laryngeal Nerve. Laryngoscope, 2001, 111, 2041-2045.	1.1	24
336	Strategic approaches to developing drug treatments for ALS. Drug Discovery Today, 2008, 13, 67-72.	3.2	24
337	The Role of Oxidized Cholesterol in Diabetes-Induced Lysosomal Dysfunction in the Brain. Molecular Neurobiology, 2016, 53, 2287-2296.	1.9	24
338	Regulation of insulin-like growth factor binding protein synthesis and secretion in human retinal pigment epithelial cells. Journal of Cellular Physiology, 1994, 158, 198-204.	2.0	23
339	Adeno-Associated Viral-Mediated Insulin-Like Growth Factor Delivery Protects Motor Neurons In Vitro. NeuroMolecular Medicine, 2005, 6, 079-086.	1.8	23
340	Natural killer cells associate with amyotrophic lateral sclersois in a sex- and age-dependent manner. JCI Insight, 2021, 6, .	2.3	23
341	The retina as a biochemical model of central nervous system regeneration. Neurochemistry International, 1980, 1, 487-500.	1.9	22
342	Ambient glucose and aldose reductase-induced myo-inositol depletion modulate basal and carbachol-stimulated inositol phospholipid metabolism and diacylglycerol accumulation in human retinal pigment epithelial cells in culture.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9712-9716.	3.3	22

#	Article	IF	Citations
343	Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2015, 12, 428-448.	2.1	22
344	Sex differences in insulin resistance, but not peripheral neuropathy, in a diet-induced prediabetes mouse model. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	22
345	Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neuroscience and Biobehavioral Reviews, 2021, 127, 958-978.	2.9	22
346	Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts. Brain, 2022, 145, 4425-4439.	3.7	22
347	Editorial [Hot Topic: Diabetic Neuropathy (Guest Editor: Eva L. Feldman)]. Current Drug Targets, 2008, 9, 1-2.	1.0	21
348	Spontaneous laryngeal reinnervation following chronic recurrent laryngeal nerve injury. Laryngoscope, 2013, 123, 2216-2227.	1.1	21
349	Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials?. Cytotherapy, 2016, 18, 1471-1475.	0.3	21
350	Characterization of Adenoviral Gene Expression in Spinal Cord after Remote Vector Delivery. Neurosurgery, 1999, 45, 131.	0.6	21
351	Neuronal survival following remote adenovirus gene delivery. Journal of Neurosurgery: Spine, 2002, 96, 212-219.	0.9	20
352	Patterning Nâ€type and Sâ€type neuroblastoma cells with Pluronic F108 and ECM proteins. Journal of Biomedical Materials Research - Part A, 2010, 93A, 673-686.	2.1	20
353	The Pleotrophic Effects of Insulin-Like Growth Factor-I on Human Spinal Cord Neural Progenitor Cells. Stem Cells and Development, 2010, 19, 1983-1993.	1.1	20
354	Diabetic cardiac autonomic neuropathy: Insights from animal models. Autonomic Neuroscience: Basic and Clinical, 2013, 177, 74-80.	1.4	20
355	Hyperglycemiaâ€•and neuropathyâ€induced changes in mitochondria within sensory nerves. Annals of Clinical and Translational Neurology, 2014, 1, 799-812.	1.7	20
356	Cardiovascular autonomic neuropathy associates with nephropathy lesions in American Indians with type 2 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 873-879.	1.2	20
357	Expenditures in the elderly with peripheral neuropathy. Neurology: Clinical Practice, 2013, 3, 421-430.	0.8	19
358	Burden of Diabetic Peripheral Neuropathy in Pima Indians With Type 2 Diabetes. Diabetes Care, 2016, 39, e63-e64.	4.3	19
359	Speckle tracking as a method to measure hemidiaphragm excursion. Muscle and Nerve, 2017, 55, 125-127.	1.0	19
360	Mitochondrial uncoupling has no effect on microvascular complications in type 2 diabetes. Scientific Reports, 2019, 9, 881.	1.6	19

#	Article	IF	Citations
361	Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes. Biology, 2020, 9, 347.	1.3	19
362	Prognosis in long-term immunosuppressive treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Clinical Epidemiology, 1992, 45, 47-52.	2.4	18
363	Suramin disrupts insulin-like growth factor-II (IGF-II) mediated autocrine growth in human SH-SY5Y neuroblastoma cells. Brain Research, 1997, 744, 199-206.	1.1	18
364	Insulin-Like Growth Factor I Induces Preferential Degradation of Insulin Receptor Substrate-2 through the Phosphatidylinositol 3-Kinase Pathway in Human Neuroblastoma Cells. Endocrinology, 2005, 146, 5350-5357.	1.4	18
365	The Evaluation of Distal Symmetric Polyneuropathy. Archives of Neurology, 2012, 69, 339.	4.9	18
366	Statin Therapy and Risk of Polyneuropathy in Type 2 Diabetes: A Danish Cohort Study. Diabetes Care, 2020, 43, 2945-2952.	4.3	18
367	Neurological sequela and disruption of neuron-glia homeostasis in SARS-CoV-2 infection. Neurobiology of Disease, 2022, 168, 105715.	2.1	18
368	Bcl-2 and N-Myc Coexpression Increases IGF-IR and Features of Malignant Growth in Neuroblastoma Cell Lines. Neoplasia, 2001, 3, 304-313.	2.3	17
369	In situ imaging of mitochondrial outer-membrane pores using atomic force microscopy. BioTechniques, 2004, 37, 564-573.	0.8	17
370	Painful Diabetic Neuropathy: Many Similarly Effective Therapies With Widely Dissimilar Costs. Annals of Internal Medicine, 2014, 161, 674.	2.0	17
371	Effect of pain in pediatric inherited neuropathies. Neurology, 2014, 82, 793-797.	1.5	17
372	Human neural stem cell transplantation into the corpus callosum of Alzheimer's mice. Annals of Clinical and Translational Neurology, 2017, 4, 749-755.	1.7	17
373	Cytoplasmic TDP43 Binds microRNAs: New Disease Targets in Amyotrophic Lateral Sclerosis. Frontiers in Cellular Neuroscience, 2020, 14, 117.	1.8	17
374	Two Dynamin-2 Genes Are Required for Normal Zebrafish Development. PLoS ONE, 2013, 8, e55888.	1.1	17
375	Extracellular Vesicles in Serum and Central Nervous System Tissues Contain microRNA Signatures in Sporadic Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience, 2021, 14, 739016.	1.4	17
376	Plasma Metabolomics and Lipidomics Differentiate Obese Individuals by Peripheral Neuropathy Status. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1091-1109.	1.8	17
377	Identification of candidate drugs for the treatment of ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 29-36.	2.3	16
378	Integrin-Linked Kinase Complexes with Caveolin-1 in Human Neuroblastoma Cellsâ€. Biochemistry, 2005, 44, 932-938.	1.2	16

#	Article	IF	Citations
379	Effect of Motor versus Sensory Nerve Autografts on Regeneration and Functional Outcomes of Rat Facial Nerve Reconstruction. Scientific Reports, 2019, 9, 8353.	1.6	16
380	Potential for promoting recurrent laryngeal nerve regeneration by remote delivery of viral gene therapy. Laryngoscope, 2012, 122, 349-355.	1.1	15
381	Importance and hurdles to drug discovery for neurological disease. Annals of Neurology, 2013, 74, 441-446.	2.8	15
382	Associations of self-reported occupational exposures and settings to ALS: a caseâ€“control study. International Archives of Occupational and Environmental Health, 2022, 95, 1567-1586.	1.1	15
383	The natural history of a ?benign? rib lesion in a patient with a demyelinating polyneuropathy and an unusual variant of poems syndrome. Muscle and Nerve, 1994, 17, 1055-1059.	1.0	14
384	Can Drug Screening Lead to Candidate Therapies for Testing in Diabetic Neuropathy?. Antioxidants and Redox Signaling, 2008, 10, 387-394.	2.5	14
385	A novel approach to study motor neurons from zebrafish embryos and larvae in culture. Journal of Neuroscience Methods, 2012, 205, 277-282.	1.3	14
386	Therapy for diabetic neuropathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 126, 317-333.	1.0	14
387	Distal Symmetric Polyneuropathy in 2020. JAMA - Journal of the American Medical Association, 2020, 324, 90.	3.8	14
388	High Dietary Fat Consumption Impairs Axonal Mitochondrial FunctionIn Vivo. Journal of Neuroscience, 2021, 41, 4321-4334.	1.7	14
389	Status epilepticus amauroticus. Neurology, 1997, 49, 1467-1469.	1.5	13
390	Remote Adenoviral Gene Delivery to the Spinal Cord: Contralateral Delivery and Reinjection. Neurosurgery, 2001, 48, 1309-1317.	0.6	13
391	Dysfunction of the Recurrent Laryngeal Nerve and the Potential of Gene Therapy. Annals of Otology, Rhinology and Laryngology, 2007, 116, 441-448.	0.6	13
392	Dual <scp>CCR2</scp>/<scp>CCR5</scp> antagonist treatment attenuates adipose inflammation, but not microvascular complications in ob/ob mice. Diabetes, Obesity and Metabolism, 2017, 19, 1468-1472.	2.2	13
393	Design-Based stereology and binary image histomorphometry in nerve assessment. Journal of Neuroscience Methods, 2020, 336, 108635.	1.3	13
394	Dietary weight loss in people with severe obesity stabilizes neuropathy and improves symptomatology. Obesity, 2021, 29, 2108-2118.	1.5	13
395	Advances in diet-induced rodent models of metabolically acquired peripheral neuropathy. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	12
396	Variable Selection with Multiply-Imputed Datasets: Choosing Between Stacked and Grouped Methods. Journal of Computational and Graphical Statistics, 2022, 31, 1063-1075.	0.9	12

#	Article	IF	Citations
397	Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis. Frontiers in Immunology, 2022, 13, 773288.	2.2	12
398	Acute effects of adrenergic-mediated ischemia on nerve conduction in subjects with type 2 diabetes. Metabolism: Clinical and Experimental, 1999, 48, 495-500.	1.5	11
399	Computational Methods for Predicting Sites of Functionally Important Dynamics. Journal of Physical Chemistry B, 2009, 113, 6613-6622.	1.2	11
400	Insulin-Like Growth Factors in the Peripheral Nervous System. Endocrinology and Metabolism Clinics of North America, 2012, 41, 375-393.	1.2	11
401	Immunohistologic analysis of spontaneous recurrent laryngeal nerve reinnervation in a rat model. Laryngoscope, 2018, 128, E117-E122.	1.1	11
402	Targeted intraspinal injections to assess therapies in rodent models of neurological disorders. Nature Protocols, 2019, 14, 331-349.	5.5	11
403	Diabetic neuropathy in children and youth: New and emerging risk factors. Pediatric Diabetes, 2021, 22, 132-147.	1.2	11
404	Differential Regulation of Insulin Receptor Substrate-2 and Mitogen-Activated Protein Kinase Tyrosine Phosphorylation by Phosphatidylinositol 3-Kinase Inhibitors in SH-SY5Y Human Neuroblastoma Cells*This work was supported by NIH Grants R29-NS-32843 and R01-NS-36778, grants from the American Diabetes Association and Juvenile Diabetes Foundation (to E.L.F.), and a grant from the Millie Schembechler Adrenal Research Fund of the University of Michigan Comprehensive Cancer Center (to) Tj ETQq0 0 0 rgBT /Overlock 10 T		11
405	Nox, Nox, Are You There? The Role of NADPH Oxidases in the Peripheral Nervous System. Antioxidants and Redox Signaling, 2022, 37, 613-630.	2.5	11
406	PTEN/MMAC1 overexpression decreases insulin-like growth factor-I-mediated protection from apoptosis in neuroblastoma cells. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 2001, 12, 371-8.	0.8	11
407	Lectin binding to neurites of goldfish retinal explants. Brain Research, 1982, 248, 347-354.	1.1	10
408	Effect of mild hyperglycemia on autonomic function in obstructive sleep apnea. Clinical Autonomic Research, 2012, 22, 1-8.	1.4	10
409	Dysregulated biodynamics in metabolic attractor systems precede the emergence of amyotrophic lateral sclerosis. PLoS Computational Biology, 2020, 16, e1007773.	1.5	10
410	Gene expression profiles of diabetic kidney disease and neuropathy in eNOS knockout mice: Predictors of pathology and RAS blockade effects. FASEB Journal, 2021, 35, e21467.	0.2	10
411	Current landscape in motoneuron regeneration and reconstruction for motor cranial nerve injuries. Neural Regeneration Research, 2020, 15, 1639.	1.6	10
412	Differential regulation of insulin receptor substrate-1 degradation during mannitol and okadaic acid induced apoptosis in human neuroblastoma cells. Cellular Signalling, 2005, 17, 769-775.	1.7	9
413	IGF-I promotes peripheral nervous system myelination. Annals of the New York Academy of Sciences, 1999, 883, 124-30.	1.8	9
414	Insulin-like Growth Factor Binding Protein Expression in Human Retinal Pigment Epithelial Cells. Annals of the New York Academy of Sciences, 1993, 692, 265-267.	1.8	8

#	Article	IF	Citations
415	Phrenic Nerve Involvement in DÃ©jÃ©rine-Sottas Disease: A Clinicopathological Case Study. Pediatric Pathology, 1994, 14, 905-911.	0.5	8
416	Intraspinal transplantation of neurogenin-expressing stem cells generates spinal cord neural progenitors. Neurobiology of Disease, 2012, 46, 59-68.	2.1	8
417	Therapeutic Hypothermia After Cardiac Arrest Without Return of Consciousness. JAMA Neurology, 2014, 71, 823.	4.5	8
418	Progress in inflammatory neuropathy â€"the legacy of Dr Jack Griffin. Nature Reviews Neurology, 2015, 11, 646-650.	4.9	8
419	Voicing the Need for Amyotrophic Lateral Sclerosis Environmental Research. JAMA Neurology, 2020, 77, 543.	4.5	8
420	The tyrosine kinase inhibitor methyl 2,5-dihydroxycinnimate disrupts changes in the actin cytoskeleton required for neurite formation. Molecular Brain Research, 1996, 43, 338-340.	2.5	7
421	Visualization of Mitochondrial DNA Replication in Individual Cells by EdU Signal Amplification. Journal of Visualized Experiments, 2010, , .	0.2	7
422	Computational methods for identifying a layered allosteric regulatory mechanism for ALSâ€causing mutations of Cuâ€Zn superoxide dismutase 1. Proteins: Structure, Function and Bioinformatics, 2011, 79, 417-427.	1.5	7
423	Novel Model to Assess Laryngeal Function, Innervation, and Reinnervation. Annals of Otology, Rhinology and Laryngology, 2011, 120, 331-338.	0.6	7
424	A new member of the multidisciplinary ALS team: The otolaryngologist. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 229-232.	2.3	7
425	Capturing cases of distal symmetric polyneuropathy in a community. Muscle and Nerve, 2012, 46, 937-942.	1.0	7
426	Histological Bulbar Manifestations in the ALS Rat. Neurodegenerative Diseases, 2015, 15, 121-126.	0.8	7
427	Defining disability: development and validation of a mobility-Disability Severity Index (mDSI) in Charcot-Marie-tooth disease. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 635-639.	0.9	7
428	Differential impact of type-1 and type-2 diabetes on control of heart rate in mice. Autonomic Neuroscience: Basic and Clinical, 2016, 194, 17-25.	1.4	7
429	The metabolic drivers of neuropathy in India. Journal of Diabetes and Its Complications, 2020, 34, 107653.	1.2	7
430	Lessons for clinical trial design in Friedreich's ataxia. Lancet Neurology, The, 2021, 20, 330-332.	4.9	7
431	PKC Activity and PKC-Î± mRNA Content Are Reduced in Serum-Deprived Human Neuroblastoma Cells without Concomitant Induction of Differentiation. Experimental Cell Research, 1993, 207, 340-347.	1.2	6
432	Diffusion tensor imaging of the sural nerve in normal controls. Clinical Imaging, 2014, 38, 648-654.	0.8	6

#	Article	IF	Citations
433	Clinical Trials of Therapies for Amyotrophic Lateral Sclerosis. JAMA Neurology, 2015, 72, 743.	4.5	6
434	Screening for novel hexanucleotide repeat expansions at ALS- and FTD-associated loci. Neurology: Genetics, 2016, 2, e71.	0.9	6
435	Magnetic resonance imaging of human neural stem cells in rodent and primate brain. Stem Cells Translational Medicine, 2021, 10, 83-97.	1.6	6
436	Amelioration of Peripheral Neuropathy in Mouse Models of Diabetes by Dietary Reversal. Diabetes, 2018, 67, .	0.3	6
437	Peptides stimulate phosphoinositide hydrolysis in human retinal pigment epithelium. Investigative Ophthalmology and Visual Science, 1993, 34, 431-7.	3.3	6
438	Automated difference image analysis of lamellar ruffling: effect of temperature change on human SH-SY5Y neuroblastoma cells. Journal of Neuroscience Methods, 2000, 102, 143-154.	1.3	5
439	Evaluation of sham nonâ€invasive ventilation for randomized, controlled trials in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2006, 7, 96-99.	2.3	5
440	Development and characterisation of an experimental recurrent laryngeal nerve injury model for the study of viral gene therapy. Journal of Laryngology and Otology, 2008, 122, 500-505.	0.4	5
441	How Neurologists Can Choose (Even More) Wisely. JAMA - Journal of the American Medical Association, 2014, 311, 1607.	3.8	5
442	Electrodiagnostic Tests in Polyneuropathy and Radiculopathy. JAMA - Journal of the American Medical Association, 2016, 315, 297.	3.8	5
443	Antisense Oligonucleotides for Duchenne Muscular Dystrophy. JAMA Neurology, 2016, 73, 259.	4.5	5
444	Neuropsychological Outcomes in Individuals With Type 1 and Type 2 Diabetes. Frontiers in Endocrinology, 2022, 13, 834978.	1.5	5
445	Review â– : Insulin-like Growth Factor-I and Apoptosis in Glial Cell Biology. Neuroscientist, 2000, 6, 39-47.	2.6	4
446	Electrodiagnostic tests are unlikely to change management in those with a known cause of typical distal symmetric polyneuropathy. Muscle and Nerve, 2017, 56, E25.	1.0	4
447	Comparison of Myelin-Associated Glycoprotein With Vincristine for Facial Nerve Inhibition After Bilateral Axotomy in a TransgenicThy1-GfpRat Model. JAMA Facial Plastic Surgery, 2019, 21, 426-433.	2.2	4
448	Differential effects of minocycline on microvascular complications in murine models of type 1 and type 2 diabetes. Journal of Translational Science, 2021, 7, .	0.2	4
449	Clinical Management of Diabetic Neuropathy. , 1998, , 89-105.		4
450	532-P: The Longitudinal Determinants of Diabetic Complications in the Pima Indians of Arizona. Diabetes, 2020, 69, .	0.3	4

#	Article	IF	Citations
451	A Role for Fatty Acids in Peripheral Neuropathy Associated with Type 2 Diabetes and Prediabetes. Antioxidants and Redox Signaling, 2022, 37, 560-577.	2.5	4
452	Systems Biology to Address Unmet Medical Needs in Neurological Disorders. Methods in Molecular Biology, 2022, 2486, 247-276.	0.4	4
453	Atlas of Neuromuscular Diseases. , 2014, , .		3
454	Diabetes and Cognitive Dysfunction. , 2015, , 189-201.		3
455	Facial Nerve Surgery in the Rat Model to Study Axonal Inhibition and Regeneration. Journal of Visualized Experiments, 2020, , .	0.2	3
456	The determinants of complication trajectories in American Indians with type 2 diabetes. JCI Insight, 2021, 6, .	2.3	3
457	Measuring neuropathy in obese populations: Challenge accepted. Reply to â€œDiagnostic accuracy of neuropathy tests in obese population remains elusiveâ€• Clinical Neurophysiology, 2018, 129, 1504-1505.	0.7	3
458	Letters to the editor. Muscle and Nerve, 1993, 16, 1129-1137.	1.0	2
459	Reversibility of Serum Removal Effects on IGF-II mRNA in Human Neuroblastoma Cells. Annals of the New York Academy of Sciences, 1993, 692, 259-261.	1.8	2
460	Neurophilins and the nervous system. , 1999, 22, 1337-1340.		2
461	The evaluation of distal symmetric polyneuropathy: utilisation and expenditures by community neurologists. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 87, jnnp-2014-307575.	0.9	2
462	Response to Comment on Jaiswal et al. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. Diabetes Care 2017;40:1226â€“1232. Diabetes Care, 2018, 41, e37-e37.	4.3	2
463	ALS/SURV: a modification of the CAFS statistic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 576-583.	1.1	2
464	Metabolism, cognition, and the brain throughout life. Neurobiology of Disease, 2020, 134, 104698.	2.1	2
465	Characterization of C9orf72 haplotypes to evaluate the effects of normal and pathological variations on its expression and splicing. PLoS Genetics, 2021, 17, e1009445.	1.5	2
466	Serum urate and cardiovascular events in the DCCT/EDIC study. Scientific Reports, 2021, 11, 14182.	1.6	2
467	Pathogenesis of Diabetic Neuropathy from the Point of View of Schwann Cell Abnormalities. , 2014, , 135-146.		2
468	Energizing the Conversation: How to Identify and Overcome Gender Inequalities in Academic Medicine. Journal of Continuing Education in the Health Professions, 2020, 40, 274-278.	0.4	2

#	Article	IF	Citations
469	The Italian multicentre study on the prevalence of distal symmetric polyneuropathy: correlation between clinical variables and nerve conduction parameters. Italian Diabetic Neuropathy Committee. Electroencephalography and Clinical Neurophysiology Supplement, 1999, 50, 546-52.	0.0	2
470	Insulin-like Growth Factor Binding Protein Expression in SH-SY5Y Neuroblastoma Cells. Annals of the New York Academy of Sciences, 1993, 692, 262-264.	1.8	1
471	The DCCT, metabolism and diabetic neuropathy: perspectives for the fourth international symposium on diabetic neuropathy. Neuroscience Research Communications, 1997, 21, 1-4.	0.2	1
472	Treatment of Diabetic Neuropathy. , 0, , 555-576.		1
473	APPLYING DATABASE TECHNOLOGY TO CLINICAL AND BASIC RESEARCH BIOINFORMATICS PROJECTS. Journal of Integrative Neuroscience, 2003, 02, 201-217.	0.8	1
474	Therapeutic Hypothermia and Targeted Temperature Management After Cardiac Arrestâ€"Reply. JAMA Neurology, 2014, 71, 1578.	4.5	1
475	A Brighter Future for Patients With Amyotrophic Lateral Sclerosis Through Imaging?. JAMA Neurology, 2014, 71, 539.	4.5	1
476	The Spectrum of Motor Neuron Diseases: From Childhood Spinal Muscular Atrophy to Adult Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2015, 12, 287-289.	2.1	1
477	Obesity and the nervous system: more questions â€“ Authors' reply. Lancet Neurology, The, 2017, 16, 774.	4.9	1
478	Exploring the optimal diagnostic threshold value of corneal nerve fibre length (CNFL) for diabetic neuropathy (DN) identification. Canadian Journal of Diabetes, 2017, 41, S62.	0.4	1
479	Scaffold for facial nerve reconstruction. , 2019, , 95-121.		1
480	Diabetic neuropathy: the future is promising. Reply to Uusitupa M, Niskanen L, Laitinen T [letter] and Coppini DV [letter]. Diabetologia, 2020, 63, 1951-1952.	2.9	1
481	A 2020 centenary perspective on neuromuscular disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 791-792.	0.9	1
482	Delivery of Interleukinâ€4â€"Encoding Lentivirus Using Multipleâ€Channel Bridges Enhances Nerve Regeneration. Laryngoscope, 2020, 130, 2802-2810.	1.1	1
483	Polyneuropathies. , 2021, , 215-261.		1
484	Traumatic Brain Injury. Neurology, 2021, 96, 357-358.	1.5	1
485	Immune-mediated vincristine-induced neuropathy: Unlocking therapies. Journal of Experimental Medicine, 2021, 218, .	4.2	1
486	Insulin-like growth factor-I prevents caspase-mediated apoptosis in Schwann cells. , 0, .		1

#	Article	IF	Citations
487	Granulomatous myositis, primary biliary cirrhosis, pancytopenia, and thymoma. , 2000, 23, 1133.		1
488	Stem Cell Therapy for Motor Neuron Disease. , 2014, , 312-328.		1
489	Polyneuropathies. , 2014, , 191-234.		1
490	Neuronal and Schwann Cell Death in Diabetic Neuropathy. , 2007, , 113-132.		1
491	Remote Adenoviral Gene Delivery to the Spinal Cord: Contralateral Delivery and Reinjection. Neurosurgery, 2001, 48, 1309-1317.	0.6	0
492	Biomedical research: a culture in crisis?. Nature Clinical Practice Neurology, 2005, 1, 61-61.	2.7	0
493	Apoptosis and Human Diseases: Molecular Mechanisms. , 2006, , 365-394.		0
494	Comment: Career guidelines promote neurologist satisfaction. Neurology, 2011, 77, 689-689.	1.5	0
495	Cytoskeleton, Axonal Transport, and the Mechanisms of Axonal Neuropathy. Advances in Neurobiology, 2011, , 657-678.	1.3	0
496	Additional Perspectives on Transforming Science Into Medicine. Academic Medicine, 2012, 87, 1311-1312.	0.8	0
497	Circuits and Circuit Disorders: Approaches to Neuromodulation. JAMA Neurology, 2015, 72, 385.	4.5	0
498	Leprosy as a Cause of Distal Symmetric Polyneuropathyâ€”Reply. JAMA - Journal of the American Medical Association, 2016, 315, 2123.	3.8	0
499	Incorrect Data Used in Statistical Analyses. JAMA Neurology, 2017, 74, 611.	4.5	0
500	Three-dimensional Imaging and Analysis of Mitochondria within Human Intraepidermal Nerve Fibers. Journal of Visualized Experiments, 2017, , .	0.2	0
501	Emergency Department Stroke Care. JAMA Neurology, 2018, 75, 257.	4.5	0
502	Response to Caro and Winter. Pain Reports, 2019, 4, e734.	1.4	0
503	Inclusion body myositis: small steps towards future advances. Lancet Rheumatology, The, 2021, 3, e5-e6.	2.2	0
504	New Neuromuscular Therapies. , 2021, , 35-43.		0

#	Article	IF	Citations
505	Motor Neuron Diseases. , 2021, , 313-320.		0
506	Genetic Testing in Neuromuscular Diseases. , 2021, , 27-33.		0
507	NADPH oxidase 5: A new player in peripheral neuropathy. Journal of the Neurological Sciences, 2021, 429, 119359.	0.3	0
508	Insulin-Like Growth Factors and Nervous System Disorders. , 2004, , 211-225.		0
509	Primary Sensory and Motor Neuron Cultures. Springer Protocols, 2009, , 161-173.	0.1	0
510	Reply to â€œDiagnosing Neuropathy in an Obese Patientâ€: Measuring neuropathy in obese populations: Nerve conduction studies. Clinical Neurophysiology, 2018, 129, 2050.	0.7	0
511	1992-P: Metabolic Factors Associated with Cognitive Function and Brain Morphology in Type 2 Diabetes. Diabetes, 2020, 69, .	0.3	0
512	2285-PUB: Hippocampal Transcriptomic Changes Due to High-Fat Diet in Prediabetic Mice. Diabetes, 2020, 69, 2285-PUB.	0.3	0
513	531-P: Metabolomics Identifies Novel Plasma Metabolomic Signatures Associated with Diabetic Neuropathy in a Cohort with Screen-Tested Type 2 Diabetes: ADDITION-Denmark. Diabetes, 2020, 69, 531-P.	0.3	0
514	537-P: Dietary Reversal Improves Peripheral Neuropathy and Gut Microbiota Profile in a Murine Model of Prediabetes and Obesity. Diabetes, 2020, 69, .	0.3	0
515	125-OR: Polyunsaturated Omega-6 Fatty Acids Reduce Axonal Mitochondrial Trafficking in Dorsal Root Ganglion Sensory Neurons. Diabetes, 2020, 69, 125-OR.	0.3	0
516	529-P: Insulin Replacement Therapy Does Not Fully Prevent Peripheral Neuropathy in Type 1 Diabetic Mice. Diabetes, 2020, 69, .	0.3	0
517	Diabetic neuropathy in children and youth. , 2022, , 185-199.		0